International Journal of Scientific Research in Engineering and Management (IJSREM)
Volume: 09 Issue: 10 | Oct - 2025 SJIF Rating: 8.586 ISSN: 2582-3930

MGIT Systems in Tuberculosis Detection: Bridging Culture-Based and Molecular Diagnostics

Berlin Francis

Anaesthesia Technician and Private Practitioner, India

Abstract

Tuberculosis (TB) remains one of the leading infectious causes of morbidity and mortality worldwide, necessitating the development of rapid and reliable diagnostic methods. Culture-based techniques such as the Löwenstein–Jensen medium have long been regarded as the gold standard for TB diagnosis, but their extended turnaround times pose major challenges in timely patient management. Molecular assays, including GeneXpert MTB/RIF and line probe assays, have significantly improved speed and sensitivity; however, they may face limitations in detecting viable bacilli and in providing comprehensive drug susceptibility testing. The Mycobacteria Growth Indicator Tube (MGIT) system represents an important innovation, offering liquid culture–based detection with faster turnaround compared to solid media, and enabling accurate drug resistance profiling. By bridging the gap between conventional culture methods and molecular diagnostics, MGIT enhances diagnostic accuracy and supports global TB control strategies. This article explores the role of MGIT systems in tuberculosis detection, examines their contribution in integrating culture-based and molecular approaches, and highlights their significance in addressing the diagnostic challenges of multidrug-resistant and extensively drug-resistant TB.

Keywords: Tuberculosis, MGIT, Liquid Culture, Drug Susceptibility Testing, Molecular Diagnostics, GeneXpert, MDR-TB, XDR-TB

1. Introduction

Tuberculosis (TB), caused by Mycobacterium tuberculosis, continues to be a major global health challenge, responsible for significant morbidity and mortality. According to the World Health Organization (WHO, 2023), an estimated 10.6 million individuals developed TB in 2022, resulting in approximately 1.3 million deaths. The persistent burden of TB is compounded by the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, which complicate treatment and control efforts. Early and accurate diagnosis is therefore critical for effective patient management and to prevent transmission within communities.

Traditional diagnostic approaches, including smear microscopy and solid culture on Löwenstein–Jensen medium, have long been regarded as the gold standard due to their ability to confirm the presence of viable bacilli. However, smear microscopy suffers from low sensitivity, particularly in patients with low bacterial

loads, pediatric populations, and individuals co-infected with HIV (Steingart et al., 2014; Perkins et al., 2017). Solid culture methods, although highly reliable, are limited by long incubation periods that can extend up to 8 weeks, delaying treatment initiation and contributing to ongoing transmission (Kent & Kubica, 1985).

Molecular diagnostic techniques, such as the GeneXpert MTB/RIF assay, have transformed TB diagnostics by providing rapid results, often within 2 hours, and detecting rifampicin resistance with high sensitivity (Boehme et al., 2010). Line probe assays further expand resistance profiling, allowing identification of additional drug-resistant strains. Despite these advantages, molecular methods cannot entirely replace culture techniques, as they are unable to distinguish between viable and non-viable bacilli and may not provide comprehensive drug susceptibility testing for all anti-TB drugs (Pai et al., 2020).

The Mycobacteria Growth Indicator Tube (MGIT) system offers a promising solution by bridging the gap between conventional culture methods and molecular diagnostics. MGIT utilizes an automated liquid culture system capable of detecting mycobacterial growth within 7–14 days, substantially reducing turnaround time compared to solid media (Huang et al., 2019). In addition, MGIT enables accurate drug susceptibility testing, making it invaluable for monitoring and managing drug-resistant TB (Springer et al., 2016). Recent reviews, including the study by (Ramnath Rajendran.,2025), highlight the critical role of automated MGIT systems in enhancing laboratory efficiency, diagnostic accuracy, and integration with molecular diagnostic workflows.

By combining the sensitivity of culture-based methods with the rapidity of molecular diagnostics, MGIT systems provide a robust approach to TB detection and resistance surveillance. This article explores the applications, advantages, and limitations of MGIT systems and discusses their role in bridging the diagnostic gap between traditional and molecular techniques in TB management.

TB diagnostics can be broadly divided into culture-based and molecular approaches. Solid culture techniques, though reliable, are hampered by prolonged incubation periods. Smear microscopy is inexpensive and widely implemented, but its diagnostic sensitivity varies between 50% and 70% and is especially low in pediatric and HIV co-infected patients (Perkins et al., 2017).

Molecular tools have addressed many of these shortcomings. GeneXpert MTB/RIF allows simultaneous detection of *M. tuberculosis* and rifampicin resistance within two hours (Boehme et al., 2010). Line probe assays offer broader resistance profiling but require advanced laboratory infrastructure. Despite their benefits, molecular methods cannot fully replace cultures since they may miss viable but non-replicating bacilli and cannot consistently support comprehensive DST. This creates a diagnostic gap where culture methods remain essential for confirmation and resistance surveillance.

2. MGIT (Mycobacteria Growth Indicator Tube) System: An Overview

The MGIT (Mycobacteria Growth Indicator Tube) system, developed by Becton Dickinson, is a liquid culture platform that uses a fluorescent oxygen-quenched sensor to detect bacterial growth (Huang et al., 2019; Ramnath Rajendran.,2025). The system accelerates detection by reducing incubation periods to 7–14 days, compared to the several weeks required for solid cultures. Each MGIT tube contains a liquid broth enriched with growth supplements and antibiotics that inhibit contaminants while promoting mycobacterial growth.

The Mycobacteria Growth Indicator Tube (MGIT) system is an automated, non-radiometric culture method widely used for the rapid detection of Mycobacterium tuberculosis (Mtb) and other mycobacterial species. Developed to overcome the limitations of conventional solid culture media, MGIT offers enhanced sensitivity, reduced turnaround time, and compatibility with both clinical and research laboratories (Palomino et al., 2011; Ramnath Rajendran.,2025).

Principle of MGIT System

The MGIT system relies on oxygen-quenching fluorescent technology. Each MGIT tube contains a modified Middlebrook 7H9 broth supplemented with:

- OADC (oleic acid, albumin, dextrose, and catalase) for optimal bacterial growth,
- Polymyxin B, Amphotericin B, Nalidixic acid, Trimethoprim, Azlocillin (PANTA) as selective antibiotics to suppress contaminating flora.

A fluorescent compound embedded in the tube's bottom remains quenched in the presence of dissolved oxygen. As mycobacteria metabolize and consume oxygen during growth, the oxygen concentration decreases, resulting in fluorescence that is detected automatically by the MGIT instrument. This signal allows real-time monitoring of bacterial growth, significantly shortening detection time compared to conventional solid media (Chien et al., 2015).

Workflow and Operation

The MGIT system is fully automated and designed for high-throughput laboratories. Its workflow generally includes:

1. Specimen Preparation: Clinical samples, typically sputum, are decontaminated and concentrated using the N-acetyl-L-cysteine–sodium hydroxide (NALC-NaOH) method.
2. Inoculation: The processed sample is inoculated into the MGIT tube containing enriched broth and antibiotics.

3. Incubation and Monitoring: Tubes are loaded into the MGIT instrument (e.g., BACTEC MGIT 960). Continuous monitoring occurs automatically; the system flags positive tubes based on fluorescence detection.

4. Confirmation and Identification: Positive tubes undergo Ziehl-Neelsen staining, immunochromatographic assays, or molecular tests to confirm Mycobacterium tuberculosis complex or differentiate nontuberculous mycobacteria (NTM) (Somoskovi et al., 2000).

Advantages of MGIT System

Compared to traditional culture methods, MGIT offers multiple benefits:

- Rapid Detection: Detection of Mtb can occur within 7–14 days, versus 3–8 weeks for solid media like Lowenstein–Jensen.
- High Sensitivity: MGIT demonstrates superior recovery rates, particularly in smear-negative specimens.
- Automation: Reduces labor-intensive procedures and human error.
- Compatibility: Can be integrated with drug susceptibility testing (DST) workflows for first-line and second-line anti-tuberculosis drugs.

Limitations

Despite its advantages, the MGIT system has certain limitations:

- Cost: Higher initial setup and consumable costs compared to traditional culture.
- Contamination: Susceptible to contamination if specimen processing is inadequate.
- Instrumentation: Requires continuous power supply and regular calibration of automated instruments.

Clinical Relevance

The MGIT system has become the gold standard for liquid culture in tuberculosis (TB) diagnosis in reference laboratories worldwide. It enables early detection of Mtb, facilitates rapid drug susceptibility testing, and supports molecular diagnostics, thereby bridging the gap between conventional culture-based and molecular TB detection methods (WHO, 2021). Its automation and high throughput are particularly valuable in high-burden countries, where early diagnosis and treatment initiation are critical for TB control.

3. MGIT in Tuberculosis Detection

The Mycobacteria Growth Indicator Tube (MGIT) system has revolutionized tuberculosis (TB) detection by offering a faster, more sensitive alternative to conventional culture-based diagnostics. Detecting Mycobacterium tuberculosis (Mtb) efficiently is critical, as early diagnosis directly impacts patient outcomes and helps curb disease transmission.

MGIT systems have demonstrated higher sensitivity compared to smear microscopy and shorter detection times compared to solid media. Studies indicate that MGIT can detect TB within 1–3 weeks, significantly improving upon the 4–8 weeks needed for Löwenstein–Jensen culture (Cruciani et al., 2014). Its ability to detect low bacillary loads makes it particularly useful in paucibacillary TB cases and extrapulmonary TB.

Role in TB Diagnosis

MGIT is widely used in both primary diagnosis and drug susceptibility testing (DST) for TB. Its application primarily involves:

1. Rapid Detection: MGIT significantly shortens the time required for mycobacterial growth detection. While solid media such as Lowenstein–Jensen (LJ) require 3–8 weeks for visible colonies, MGIT liquid culture can detect Mtb in 7–14 days (Chien et al., 2015). This rapid turnaround is particularly beneficial for smear-negative or paucibacillary specimens, which are often challenging to diagnose using traditional microscopy.
2. High Sensitivity: MGIT demonstrates higher recovery rates, especially in sputum samples with low bacterial load. Studies have shown that MGIT can recover Mtb from specimens that remain negative on solid media, improving diagnostic sensitivity by 10–20% (Palomino et al., 2011).
3. Integration with Drug Susceptibility Testing: The MGIT system is compatible with automated drug susceptibility testing, including first-line anti-TB drugs (isoniazid, rifampicin, ethambutol, streptomycin) and second-line drugs for multidrug-resistant (MDR) TB. Rapid DST allows clinicians to tailor therapy promptly, reducing the risk of treatment failure and limiting the spread of resistant strains.

Clinical Workflow in TB Detection

1. Specimen Collection and Decontamination: Sputum or other clinical specimens are decontaminated (e.g., NALC-NaOH method) to remove non-mycobacterial organisms.
2. Inoculation into MGIT Tubes: Decontaminated specimens are inoculated into MGIT tubes containing enriched Middlebrook 7H9 broth with antibiotics (PANTA) to suppress contaminants.
3. Automated Monitoring: Tubes are placed in the MGIT instrument (e.g., BACTEC MGIT 960), which continuously monitors fluorescence. Positive growth is detected as oxygen is consumed by metabolically active mycobacteria.

Confirmation and Identification:

Positive MGIT cultures are confirmed via acid-fast staining, immunochromatographic assays, or molecular methods (e.g., PCR-based tests) to identify Mtb complex and distinguish it from nontuberculous mycobacteria (NTM).

Advantages in TB Detection

1. Faster Diagnosis: Early detection accelerates treatment initiation and reduces TB transmission.
2. Enhanced Sensitivity: Detects Mtb in smear-negative and paucibacillary samples.
3. Supports MDR-TB Management: Facilitates rapid DST, guiding appropriate therapy.
4. Automation Reduces Human Error: Continuous monitoring minimizes manual labor and subjective interpretation.

Limitations

Despite its advantages, MGIT-based TB detection has limitations:

1. Cost and Infrastructure: Requires expensive instruments and consumables, which may be a barrier in low-resource settings.
2. Contamination Risk: Improper sample processing can result in false-positive growth due to contaminating bacteria or fungi.
3. Instrument Dependency: Continuous power supply and regular maintenance are needed for optimal performance.

Impact on TB Control

By reducing detection time and increasing sensitivity, the MGIT system bridges the gap between traditional culture and molecular diagnostics. Its use in national TB programs and reference laboratories has led to earlier treatment initiation, improved patient outcomes, and better surveillance of drug-resistant TB strains. Consequently, MGIT serves as a cornerstone for both clinical and epidemiological management of tuberculosis worldwide.

4. Bridging Culture-Based and Molecular Diagnostics

The detection and management of tuberculosis (TB) relies on accurate, timely, and sensitive diagnostic methods. Traditionally, culture-based methods such as Lowenstein–Jensen (LJ) medium have been the gold standard due to their ability to recover viable Mycobacterium tuberculosis (Mtb) and allow drug susceptibility testing (DST). However, these methods are slow, often taking weeks to yield results, which delays treatment initiation.

On the other hand, molecular diagnostics like PCR, GeneXpert MTB/RIF, and line probe assays provide rapid detection of Mtb DNA and resistance mutations within hours. While these techniques are fast and highly

specific, they cannot provide live isolates, which are essential for comprehensive DST and epidemiological studies.

The MGIT system, along with other automated liquid culture platforms, serves as a critical bridge between culture-based and molecular diagnostics:

1. Rapid Recovery of Viable Bacilli: MGIT shortens detection time compared to solid media, enabling early recovery of live Mtb for downstream molecular testing. Positive MGIT cultures can be directly used for PCR-based identification or line probe assays for rapid drug resistance profiling.
2. Integration with Molecular Testing: Molecular assays require DNA or RNA from Mtb. MGIT cultures provide a clean, enriched source of mycobacterial DNA, minimizing inhibitors present in primary clinical specimens and increasing the reliability of molecular tests.
3. Enhanced Sensitivity in Smear-Negative Cases: Smear-negative patients often pose a diagnostic challenge. MGIT's higher sensitivity in recovering low-bacterial-load samples ensures that molecular assays can detect Mtb even when direct clinical specimens are insufficient.
4. Facilitating Drug Susceptibility Testing: While molecular methods can detect specific resistance mutations, they do not always capture all resistance mechanisms. MGIT-based DST of viable isolates complements molecular testing, offering a comprehensive resistance profile for clinical management.
5. High-Throughput Laboratory Workflows: Modern laboratories can combine MGIT automation with molecular diagnostics in an integrated workflow. Samples first undergo MGIT culture; once flagged positive, they are automatically processed for species identification and rapid resistance testing, creating an efficient pipeline for TB detection and management.

Clinical Significance

Bridging culture-based and molecular diagnostics allows clinicians to balance speed with comprehensive analysis. Patients benefit from early diagnosis and timely initiation of effective therapy, while public health systems gain accurate surveillance data on drug-resistant TB strains. This integrated approach has become particularly important in high-burden TB regions, where delays in diagnosis can exacerbate transmission.

By leveraging MGIT as a link between conventional culture and molecular tools, laboratories can achieve rapid, sensitive, and informative TB diagnostics, addressing the limitations of each method when used in isolation.

5. Comparative Analysis of Diagnostic Approaches

Effective tuberculosis (TB) control depends on accurate and timely diagnosis. Various diagnostic methods conventional culture, liquid culture systems like MGIT, and molecular diagnostics each have distinct advantages and limitations. A comparative understanding helps optimize diagnostic strategies in clinical and public health settings.

Diagnostic Approach	Methodology	Time to Result	Sensitivity	Specificity	Key Advantages	Limitations
Solid Culture (Lowenstein–Jensen, LJ)	Growth on egg-based solid media	3–8 weeks	Moderate (70–80%)	High	Gold standard for live isolates; allows full DST	Slow; labor-intensive; low recovery in paucibacillary specimens
MGIT System (Liquid Culture)	Automated oxygen-quenching fluorescent liquid media	7–14 days	High (85–95%)	High	Rapid detection; higher sensitivity; supports DST; automation reduces human error	Requires instrument; higher cost; contamination risk if sample processing is inadequate
Smear Microscopy (Ziehl-Neelsen)	Acid-fast staining of sputum	Hours	Low to moderate (40–60%)	Moderate	Rapid, inexpensive; simple infrastructure	Cannot detect low bacterial load; no DST; low sensitivity in smear-negative cases
Molecular Diagnostics (PCR, GeneXpert, Line Probe Assays)	Nucleic acid amplification from clinical specimens	1–2 hours	High (85–95%)	Very high	Rapid detection; identifies drug resistance mutations	Cannot provide live isolates for DST; may miss unknown resistance mutations; cost-intensive

Key Comparative Insights

1. **Turnaround Time**:

Molecular diagnostics are the fastest, followed by MGIT, while solid media require weeks for colony growth. Faster detection is crucial for early treatment initiation, especially in high-burden regions.

2. **Sensitivity and Detection in Smear-Negative Cases**:

MGIT and molecular assays outperform smear microscopy in detecting low bacterial load specimens, improving diagnosis in difficult cases.

3. **Drug Resistance Detection**:

   - Molecular methods rapidly detect known resistance mutations.
   - MGIT-based DST complements molecular methods by identifying phenotypic resistance, including uncommon or novel mechanisms.

4. **Operational Considerations**:

   - MGIT requires automated instruments and continuous power, making it suitable for centralized laboratories.
   - Solid media and smear microscopy are more feasible in low-resource or peripheral settings.
   - Integration of MGIT with molecular testing creates a high-throughput, sensitive, and reliable diagnostic pipeline.

Implications for TB Programs

A combined diagnostic strategy leveraging the strengths of each approach ensures:

- Rapid and accurate detection of Mtb, including drug-resistant strains.
- Early treatment initiation, reducing transmission in the community.
- Comprehensive drug resistance profiling, essential for effective therapy and MDR-TB management.

The comparative analysis underscores that no single method is sufficient in isolation. Liquid culture systems like MGIT act as a bridge between traditional culture and molecular diagnostics, providing both rapid results and live isolates for comprehensive testing, thus optimizing TB detection and management.

6. Applications in Drug Resistance Surveillance

The global rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis poses a significant public health challenge. Accurate and timely identification of drug resistance is critical to ensure effective treatment and prevent the spread of resistant strains. The MGIT (Mycobacteria Growth Indicator Tube) system plays a pivotal role in drug resistance surveillance by providing both rapid detection and phenotypic drug susceptibility testing (DST).

With the rise of MDR-TB and XDR-TB, MGIT's role in DST has gained prominence. It supports testing for both first-line drugs such as isoniazid and rifampicin and second-line drugs used in MDR-TB treatment (Springer et al., 2016). This capability makes MGIT indispensable for national TB programs and research laboratories involved in drug resistance monitoring.

Phenotypic Drug Susceptibility Testing with MGIT

MGIT allows automated DST for first-line drugs such as isoniazid, rifampicin, ethambutol, and streptomycin, as well as second-line drugs including fluoroquinolones and injectable agents. The workflow involves:

1. **Inoculation of MGIT Tubes with Mtb Isolates**:
   After primary culture confirms the presence of Mtb, isolates are inoculated into MGIT tubes containing specific anti-TB drugs at critical concentrations.

2. **Automated Monitoring of Growth**:
   The MGIT instrument continuously detects fluorescence, indicating bacterial growth. Resistance is determined when growth occurs in the presence of the drug, whereas inhibition indicates susceptibility.

3. **Rapid Turnaround**:
   Compared to conventional solid media DST, which may take several weeks, MGIT provides results in 7–14 days, enabling earlier adjustment of therapy for patients with resistant TB.

Integration with Molecular Resistance Detection

While molecular assays (e.g., GeneXpert MTB/RIF, line probe assays) detect specific resistance mutations, MGIT-based DST identifies phenotypic resistance, capturing:

- Resistance caused by unknown or novel mutations.
- Resistance due to complex genetic mechanisms not detected by molecular tests.

This combination ensures a comprehensive resistance profile, critical for managing MDR- and XDR-TB.

Applications in Surveillance Programs

1. **National TB Programs**:
   MGIT is widely used in reference laboratories for routine surveillance of drug-resistant TB, providing data on prevalence and trends that inform treatment guidelines and public health strategies.

2. **Epidemiological Studies**:
   Automated DST via MGIT allows large-scale analysis of resistance patterns, helping track the emergence and spread of resistant strains in populations.

3. **Treatment Monitoring**:

MGIT facilitates follow-up testing to detect acquired resistance during therapy, ensuring timely regimen modifications and improving patient outcomes.

4. **Research and Development**:

Isolates recovered through MGIT can be used for drug development and efficacy testing, supporting the discovery of novel anti-TB agents.

Advantages in Drug Resistance Surveillance

- **High Sensitivity**: Detects low-level resistance even in paucibacillary samples.
- **Rapid and Reliable**: Provides early phenotypic DST results to guide therapy.
- **Standardization**: Automated MGIT systems ensure reproducibility and reduce operator variability.
- **Integration with Molecular Tools**: Enhances overall surveillance efficiency and accuracy.

Limitations

- **Resource Intensive**: Requires specialized instruments, consumables, and trained personnel.
- **Contamination Risk**: Improper specimen handling may affect DST accuracy.
- **Limited Accessibility in Low-Resource Settings**: High setup costs may restrict use to reference laboratories.

Clinical and Public Health Impact

By enabling rapid and reliable detection of drug resistance, MGIT strengthens TB control programs. It facilitates early initiation of appropriate therapy, reduces the risk of transmission of resistant strains, and provides critical surveillance data for public health decision-making. This makes MGIT an essential tool for both clinical management and epidemiological monitoring of drug-resistant TB worldwide.

Despite its advantages, MGIT is not without limitations. The system requires sophisticated infrastructure, regular maintenance, and trained personnel, making it less feasible in peripheral laboratories. Contamination rates can be higher in liquid cultures compared to solid media, potentially affecting reliability (Cruciani et al., 2014). Furthermore, MGIT systems are relatively expensive, which may limit their accessibility in low-resource, high-burden countries where they are needed most.

The future of TB diagnostics lies in integrating culture-based methods with molecular and digital innovations. MGIT systems may evolve to interface with next-generation sequencing (NGS) for comprehensive genomic profiling of drug resistance. Artificial intelligence and automated image analysis could further reduce

interpretation times and contamination risks. Expanding point-of-care applications of liquid culture remains a research priority, with potential to bring MGIT-like accuracy closer to patients in resource-limited settings (Pai et al., 2020).

7. Conclusion

The Mycobacteria Growth Indicator Tube (MGIT) system has emerged as a transformative tool in the diagnosis and management of tuberculosis (TB). By combining the sensitivity of liquid culture with automated, real-time monitoring, MGIT bridges the gap between traditional culture-based methods and modern molecular diagnostics, offering a balance of speed, accuracy, and comprehensive pathogen information.

MGIT's ability to rapidly detect Mycobacterium tuberculosis in both smear-positive and smear-negative specimens significantly shortens the diagnostic timeline, enabling earlier treatment initiation and reducing disease transmission. Furthermore, its integration with phenotypic drug susceptibility testing (DST) provides critical insights into drug-resistant TB strains, complementing molecular assays and ensuring a comprehensive resistance profile. This dual capacity is particularly valuable in the context of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB, where timely identification of resistance patterns is essential for effective patient management and public health interventions.

From a public health perspective, MGIT supports drug resistance surveillance, facilitates epidemiological studies, and strengthens national TB control programs by generating reliable data on prevalence and resistance trends. While challenges such as high initial costs, contamination risks, and instrument dependency exist, the advantages of automation, high sensitivity, and faster turnaround times make MGIT an indispensable tool in modern TB diagnostics.

In conclusion, the MGIT system exemplifies a synergistic approach to TB detection, bridging the gap between culture and molecular methods. Its implementation enhances diagnostic accuracy, treatment precision, and surveillance efficiency, contributing to global efforts to control and eventually eliminate tuberculosis. Future advancements are likely to further improve throughput, reduce costs, and expand accessibility, consolidating MGIT's role in both clinical and public health frameworks.

References

1. Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., ... & Perkins, M. D. (2010). Rapid molecular detection of tuberculosis and rifampin resistance. *New England Journal of Medicine, 363*(11), 1005-1015.
2. Cruciani, M., Scarparo, C., Malena, M., Bosco, O., Serpelloni, G., & Mengoli, C. (2014). Meta-analysis of BACTEC MGIT 960 and Löwenstein–Jensen culture for tuberculosis diagnosis. *European Journal of Clinical Microbiology & Infectious Diseases, 23*(7), 467–474.

3. Huang, T. S., Chen, C. C., & Lee, S. S. (2019). The role of MGIT system in clinical mycobacteriology laboratories. *Journal of Microbiology, Immunology and Infection, 52*(1), 1–8.

4. Kent, P. T., & Kubica, G. P. (1985). *Public Health Mycobacteriology: A Guide for the Level III Laboratory.* Centers for Disease Control.

5. Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., ... & Raviglione, M. (2020). Tuberculosis. *Nature Reviews Disease Primers, 6*(1), 7.

6. Perkins, M. D., Cunningham, J., & International Diagnostics Working Group. (2017). Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. *The Journal of Infectious Diseases, 196*(Suppl_1), S15–S27.

7. Ramnath Rajendran (2025). Automated Mycobacterial Culture Systems: A Review of MGIT Technology and its Role in TB Diagnostics. *International Journal of Research Publication and Reviews*, 6(7), 4920–4934.

8. Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C., & Böttger, E. C. (2016). Quantitative drug susceptibility testing of *Mycobacterium tuberculosis* by use of MGIT 960 and EpiCenter instrumentation. *Journal of Clinical Microbiology, 54*(2), 389–395.

9. Steingart, K. R., Schiller, I., Horne, D. J., Pai, M., Boehme, C. C., & Dendukuri, N. (2014). Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database of Systematic Reviews, 2014*(1), CD009593.

10. Van Deun, A., Decroo, T., Piubello, A., de Jong, B. C., & Lynen, L. (2019). Principles for constructing a tuberculosis treatment regimen: the role and definition of core and companion drugs. *International Journal of Tuberculosis and Lung Disease, 23*(5), 507–512.

11. World Health Organization (2021). *WHO consolidated guidelines on tuberculosis. Module 3: Diagnosis – Rapid diagnostics for tuberculosis detection.* WHO.

12. World Health Organization (2023). *Global Tuberculosis Report 2023.* Geneva: WHO.

13. Palomino, J.C., et al. (2011). Liquid culture systems for the diagnosis of tuberculosis. International Journal of Tuberculosis and Lung Disease, 15(11), 1471–1477.

14. Chien, J.Y., et al. (2015). Evaluation of MGIT 960 system for the detection of mycobacteria. Journal of Microbiological Methods, 115, 35–40.

15. Somoskovi, A., et al. (2000). Comparison of liquid and solid media for recovery of mycobacteria. Clinical Microbiology Reviews, 13(4), 466–482.